JP2013538856A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538856A5
JP2013538856A5 JP2013531769A JP2013531769A JP2013538856A5 JP 2013538856 A5 JP2013538856 A5 JP 2013538856A5 JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013538856 A5 JP2013538856 A5 JP 2013538856A5
Authority
JP
Japan
Prior art keywords
interferon
pharmaceutical composition
composition according
pegylated
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013531769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538856A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/053681 external-priority patent/WO2012044684A2/en
Publication of JP2013538856A publication Critical patent/JP2013538856A/ja
Publication of JP2013538856A5 publication Critical patent/JP2013538856A5/ja
Pending legal-status Critical Current

Links

JP2013531769A 2010-10-01 2011-09-28 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 Pending JP2013538856A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38900910P 2010-10-01 2010-10-01
US61/389,009 2010-10-01
PCT/US2011/053681 WO2012044684A2 (en) 2010-10-01 2011-09-28 Interferon-beta for use as monotherapy or in combination with other cancer therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016181104A Division JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Publications (2)

Publication Number Publication Date
JP2013538856A JP2013538856A (ja) 2013-10-17
JP2013538856A5 true JP2013538856A5 (enExample) 2014-11-13

Family

ID=45890011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013531769A Pending JP2013538856A (ja) 2010-10-01 2011-09-28 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
JP2016181104A Pending JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016181104A Pending JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Country Status (9)

Country Link
US (2) US20120082647A1 (enExample)
EP (1) EP2621516B1 (enExample)
JP (2) JP2013538856A (enExample)
AU (2) AU2011308906B2 (enExample)
CA (1) CA2813304A1 (enExample)
ES (1) ES2587837T3 (enExample)
MX (1) MX2013003599A (enExample)
NZ (2) NZ608630A (enExample)
WO (1) WO2012044684A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
WO2014128701A1 (en) 2013-02-20 2014-08-28 Yeda Research And Development Co. Ltd. Interferon treatment targeting mutant p53 expressing cells
WO2014130811A1 (en) * 2013-02-22 2014-08-28 Biogen Idec Ma Inc Interferon beta formulation
EP3126379B1 (en) * 2014-04-04 2019-05-22 Ares Trading SA Novel ifn beta protein analogs
EP3222276B1 (en) * 2014-11-19 2021-04-07 National Defense Medical Center Pharmaceutical composition for treating cancer and biomarker for drug screening
KR102666000B1 (ko) 2016-07-29 2024-05-14 서울대학교 산학협력단 cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물
CN121197419A (zh) * 2019-09-30 2025-12-26 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
CN112569358B (zh) * 2019-09-30 2022-06-28 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU680650B2 (en) 1993-01-06 1997-08-07 Ipsen Manufacturing Ireland Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CN101062419B (zh) * 1998-10-16 2016-06-29 生物基因Ma公司 干扰素-β-1a的聚合物缀合物及其使用
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
PE20071042A1 (es) * 2005-11-04 2007-10-12 Wyeth Corp Producto farmaceutico que comprende temsirolimus y malato de sunitinib
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use

Similar Documents

Publication Publication Date Title
JP2013538856A5 (enExample)
Kleinert et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study
ECSP077356A (es) Forma termodinámicamente estable de una sal tosilato
HUE035931T2 (hu) N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása
AR067701A1 (es) Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2
MX2009002642A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluoro fenoxi]-n-metilpiridina-2-carboxamida monohidrato.
JP2011513196A5 (enExample)
PL2042041T3 (pl) Zastosowanie kwasu benzoesowego i tymolu, eugenolu i piperyny w żywieniu zwierząt
JP2015511632A5 (enExample)
EP2210601A4 (en) AGAINST TIREDNESS WITH AN AMINO ACID COMPOSITION
JP2015533163A5 (enExample)
BR112012017691A2 (pt) nova composição
JP2017222722A5 (enExample)
EP2724711A3 (de) Haarpflegemittel mit ausgewählten Aminosäuren und/oder ausgewählten Oligopeptiden und einem ausgewählten kationischen Keratinhydrolysat
NO20064050L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient
JP2011068692A5 (enExample)
CN103655242B (zh) 水解小麦蛋白洗发露
MX2013006031A (es) Formulacion liposomal de dalcetrapib.
JP2009530360A5 (enExample)
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
Winther et al. Can median nail dystrophy be an adverse effect of alitretinoin treatment?
CY1111257T1 (el) Χρηση της αγομελατινης για τη ληψη φαρμακων προοριζομενων για τη θεραπεια των διπολικων διαταραχων
HRP20161158T1 (hr) Interferon beta za liječenje bolesti donjeg dišnog sustava izazvane gripom
CO6592037A2 (es) Combinación de un aine y un aminoacido
JP2017007966A5 (enExample)